polidocanol

Drug Overview

In the specialized field of hematology and vascular medicine, polidocanol is a vital tool for treating disorders of the peripheral veins. It belongs to the Sclerosing Agent drug class. Unlike many hematological drugs that act systemically on the blood itself, polidocanol is used for a localized TARGETED THERAPY approach to destroy diseased blood vessels from the inside out.

Polidocanol is a non-ionic surfactant that serves a dual purpose: it acts as both a chemical irritant for the vein lining and a local anesthetic. This makes the treatment relatively painless for the patient. By triggering a controlled response within the vessel, polidocanol allows physicians to eliminate unsightly and uncomfortable veins without the need for invasive surgery.

• Generic Name: polidocanol
• US Brand Names: Asclera, Varithena
• Route of Administration: Intravenous (specifically via intraluminal injection or as a microfoam)
• FDA Approval Status: FDA-approved for the treatment of small varicose veins (spider veins and reticular veins) and larger saphenous vein systems.

What Is It and How Does It Work? (Mechanism of Action)

To understand how polidocanol works, we must look at the anatomy of the vein. The innermost lining of a blood vessel is called the endothelium. In healthy veins, this lining is smooth, allowing blood to flow back to the heart efficiently. In varicose veins, the valves fail, and the blood pools, stretching the vessel walls.

Polidocanol acts as a “detergent-type” sclerosing agent. When injected into the diseased vein, it performs a high-precision TARGETED THERAPY at the molecular level through the following steps:

1. Endothelial Destruction: The drug molecule has a “water-loving” head and a “fat-loving” tail. This structure allows it to dissolve the lipids (fats) that make up the cell membranes of the endothelial cells.
2. Chemical Irritation: As the cell membranes dissolve, the lining of the vein is stripped away. This exposes the underlying tissue of the vein wall.
3. Controlled Thrombus Formation: In response to this damage, the body initiates a localized clotting process. Unlike a dangerous blood clot, this is a controlled response designed to glue the vein walls together.
4. Obliteration and Fibrosis: Over time, the vein collapses. The blood is naturally rerouted to healthier veins nearby. The treated vein is eventually replaced by a small amount of fibrous (scar) tissue, which the body slowly absorbs.

Because polidocanol also possesses anesthetic properties (it is chemically related to certain local painkillers), it numbs the area immediately upon injection. This reduces the “burning” sensation often associated with older sclerosing agents like hypertonic saline.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for polidocanol is the sclerotherapy of varicose veins. Within the hematology and vascular specialty, it is specifically indicated for:

• Spider Veins: Very small veins (less than 1 mm in diameter).
• Reticular Veins: Small, blue-green veins (1 to 3 mm in diameter) that often feed into spider veins.
• Great Saphenous Vein System: In its microfoam form (Varithena), it is approved to treat larger, more complex varicose veins that were previously only treatable via surgical “stripping.”

Other Approved & Off-Label Uses

While primarily used for leg veins, polidocanol is occasionally used off-label for other vascular malformations, including:

• Esophageal Varices: To stop bleeding in the veins of the esophagus in patients with liver cirrhosis.
• Vascular Malformations: Treating certain types of birthmarks or “tangles” of blood vessels in pediatric and adult patients.
• Hemorrhoids: In some international markets, polidocanol is used to shrink symptomatic internal hemorrhoids.

Dosage and Administration Protocols

The dosage of polidocanol is highly individualized based on the size and number of veins being treated. Healthcare professionals typically use the lowest concentration effective for the vein size.

Vein Type	Recommended Concentration	Maximum Volume per Session
Spider Veins (<1 mm)	0.5% solution	Up to 10 mL total
Reticular Veins (1-3 mm)	1.0% solution	Up to 10 mL total
Large Varicose Veins	1.0% – 3.0% (Foam)	Varies by manufacturer (usually 5-15 mL)

Important Adjustments:

• Maximum Dosing: To avoid systemic toxicity, the total amount of polidocanol injected in a single treatment session should not exceed 2 mg per kilogram of the patient’s body weight.
• Renal/Hepatic Insufficiency: While polidocanol is primarily metabolized by the liver and excreted by the kidneys, no specific dose adjustments are usually required because the systemic levels remain extremely low after localized injection. However, caution is advised in patients with severe organ failure.
• Infusion Rate: Polidocanol is never “infused” like a standard IV drug. It is injected slowly in small aliquots (0.1 to 0.5 mL per injection site) to ensure it stays in contact with the vein wall.

Clinical Efficacy and Research Results

Clinical data from 2020 through 2026 continues to demonstrate that polidocanol is the “gold standard” for liquid and foam sclerotherapy. In major clinical trials (such as the EASI study), polidocanol achieved a successful “occlusion rate” (vein closure) of over 95% for spider and reticular veins.

Recent research has focused on the use of polidocanol microfoam for larger veins. Studies published in late 2025 showed that foam sclerotherapy with polidocanol was nearly as effective as endovenous laser treatment for larger saphenous veins, but with significantly less bruising and a faster return to daily activities. Numerical data from recent patient-reported outcome trials indicate that 88% of patients reported “significant improvement” in leg heaviness and aching within 30 days of treatment.

Safety Profile and Side Effects

Black Box Warning

There is no “Black Box Warning” for polidocanol. However, it must be used with extreme caution to avoid accidental injection into an artery, which can cause severe tissue death (necrosis) or limb loss.

Common side effects (>10%)

• Injection Site Reactions: Temporary redness, bruising, or mild swelling.
• Hyperpigmentation: Small “tan” or brown streaks on the skin where the vein used to be. This usually fades within 6 to 12 months.
• Neovascularization: The appearance of tiny “mats” of new, very fine red vessels (matting).

Serious adverse events

• VTE/Thrombosis Risk: While the drug is meant to cause a local clot, there is a small risk that the sclerosing agent or a clot could travel to the deep veins, causing Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE).
• Hypersensitivity: Severe allergic reactions (anaphylaxis) are rare but possible.
• Tissue Necrosis: If the drug leaks outside the vein (extravasation) or enters a small artery, it can cause skin ulcers.
• Stroke/TIA: Rare reports of neurological events have been linked to the use of foam sclerotherapy in patients with a “hole in the heart” (patent foramen ovale).

Management Strategies

If hyperpigmentation occurs, topical treatments or specialized lasers can be used to speed up fading. To prevent DVT, patients are instructed to walk immediately after the procedure. If an allergic reaction is suspected, the procedure is stopped, and emergency medications (epinephrine, antihistamines) are administered.

Research Areas

In 2026, research is expanding into the use of polidocanol for non-cosmetic hematology complications. Active clinical trials are investigating “catheter-directed” foam sclerotherapy to treat pelvic congestion syndrome and varicoceles. Furthermore, scientists are exploring novel delivery systems, such as ultrasound-guided automated injection devices, to further increase the safety and precision of this TARGETED THERAPY. Researchers are also looking at the combination of polidocanol with anti-inflammatory agents to reduce the incidence of post-treatment matting and hyperpigmentation.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before undergoing sclerotherapy, patients typically require:

• Duplex Ultrasound: To map the venous system and ensure there is no pre-existing Deep Vein Thrombosis.
• Visual Exam: To categorize the veins as spider, reticular, or varicose.
• CBC and Organ Function: Baseline blood work to ensure overall health.

Precautions during treatment

• Vigilance for Thromboembolism: Patients must be monitored for sudden calf pain or shortness of breath after the procedure.
• Compression Therapy: The use of medical-grade compression stockings is essential for 1 to 2 weeks post-treatment to keep the treated vein walls pressed together.
• Physical Activity: Patients should avoid heavy lifting or high-impact exercise for several days but must walk for 20-30 minutes daily.

“Do’s and Don’ts” List

• DO walk for at least 15-20 minutes immediately following your appointment.
• DO wear your compression stockings exactly as your doctor instructs.
• DO inform your provider if you have a history of blood clots or heart defects.
• DON’T take hot baths, enter saunas, or use whirlpools for at least 48 hours.
• DON’T expose the treated area to direct sunlight for 2 weeks, as this can increase the risk of dark spots (hyperpigmentation).
• DON’T sit or stand in one place for long periods for the first week after treatment.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Always consult with a specialized vascular surgeon or hematologist to determine if sclerotherapy is appropriate for your specific condition. If you experience sudden chest pain or leg swelling after treatment, seek emergency medical care immediately.